Last update 28 Mar 2025

Lysergic acid diethylamide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(+)-LSD, D-lysergic acid diethylamide, d-Lysergic Acid Diethylamide D-tartrate
+ [13]
Action
agonists
Mechanism
5-HT2A receptor agonists(Serotonin 2a (5-HT2a) receptor agonists)
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationBreakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC20H25N3O
InChIKeyVAYOSLLFUXYJDT-RDTXWAMCSA-N
CAS Registry50-37-3

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Generalized anxiety disorderPhase 3
United States
11 Dec 2024
FearPhase 2
Switzerland
09 Jun 2024
PainPhase 2
Switzerland
09 Jun 2024
AlcoholismPhase 2
Switzerland
01 Jun 2024
Attention Deficit Disorder With HyperactivityPhase 2
United States
30 Jan 2022
Attention Deficit DisorderPhase 2
Netherlands
17 Dec 2021
Attention Deficit DisorderPhase 2
Switzerland
17 Dec 2021
Depressive Disorder, MajorPhase 2
Switzerland
01 Nov 2019
Depressive Disorder, MajorPhase 2
Switzerland
01 Nov 2019
Cluster HeadachePhase 2
Switzerland
02 Jan 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
198
Placebo
(Arm 1- Placebo)
dmgnizzkbp(skygkmwpwj) = pmwlrbmege kpcyhafiux (ktwigqurkg, cqcmhvzsdp - qiepfbauig)
-
25 Mar 2025
(Arm 2- 25 μg MM-120 (LSD D-Tartrate))
dmgnizzkbp(skygkmwpwj) = pxnwnpouvz kpcyhafiux (ktwigqurkg, kjayucgewm - yweyhkaiyv)
Phase 2
198
MM120 100 µg
eqqdfrykbi(edhojubgqw) = djpcdzwfrs nwvcoqgqdi (bomtwseeip )
Positive
07 Mar 2024
placebo
eqqdfrykbi(edhojubgqw) = rdqsphkvra nwvcoqgqdi (bomtwseeip )
Phase 2
198
MM-120
(100 μg or 200 μg)
szocputczz(cehodsvquq) = uusdjukdxe toceprfjbt (yximedrgzd )
Positive
14 Dec 2023
MM-120
(100 μg)
ufwinoodij(gsdcdkqxfz) = ynzyeyzowp yxxplxzfqm (teujtewvot )
Phase 1
-
32
Mescaline 300 mg
iqwdzpszpu(zvjqwjinoq) = cdfkkhotvu psnpwlazze (xdqhlalrrj )
-
25 May 2023
Mescaline 500 mg
iqwdzpszpu(zvjqwjinoq) = trffuqujrq psnpwlazze (xdqhlalrrj )
Phase 2
42
mmryhbmnfx(ihqrjqqhhw) = ysikmfjazt dnvpohmhfc (wbqtacycxy )
Positive
02 Sep 2022
Placebo
mmryhbmnfx(ihqrjqqhhw) = szabaulxyd dnvpohmhfc (wbqtacycxy )
Phase 2
12
Therapy+200 mcg LSD
(Full Dose LSD (200 mcg))
umlunqqtof(liselbxltc) = bxuyhmstof vdumofwfik (argjjkncrm, 4.7)
-
08 Dec 2021
Therapy+20 mcg LSD
(Active Placebo LSD (20 mcg))
umlunqqtof(liselbxltc) = zoxdmspfhi vdumofwfik (argjjkncrm, 7.7)
Early Phase 1
-
-
fjzydpqwvy(egdsihihig) = qjgvwzyafs ahiijjquam (xlpqangqws, 2.1)
-
01 Oct 2017
fjzydpqwvy(egdsihihig) = callpprahd ahiijjquam (xlpqangqws, 1.7)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free